Cash Flow Statement (Annual)
HRS / Harris Corp. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Net Income Loss||561,600||588,000||30,600||113,000||534,800||334,000||324,000||-|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Depreciation And Amortization||165,700||212,000||260,300||220,600||204,300||233,000||229,000||183,000|
|Amortization Of Intangible Assets From Acquisition||-||-||-||-||0||11,000||132,000||128,000|
|Share Based Compensation||35,300||46,100||34,700||32,900||35,400||37,000||39,000||42,000|
|Pension Expense Reversal Of Expense Noncash||-||-||-||-||-||-1,000||-26,000||-97,000|
|Asset Impairment Charges||-||-||-||-||0||46,000||367,000||240,000|
|Gain Loss On Sale Of Business||-||-||-||-||-||9,000||10,000||-14,000|
|Increase Decrease In Operating Assets|
|Increase Decrease In Accounts Receivable||-||-||-||-||-||-||-||-|
|Increase Decrease In Inventories||13,900||64,700||25,200||54,100||-50,100||-20,000||28,000||-28,000|
|Increase Decrease In Operating Liabilities|
|Increase Decrease In Accounts Payable||-||-||-||-||-||-||-||-|
|Increase Decrease In Customer Advances||53,000||47,600||23,800||82,500||-42,000||-48,000||-96,000||-42,000|
|Increase Decrease In Income Taxes||-||-||-||-||-||-2,000||199,000||131,000|
|Increase Decrease In Other Operating Capital Net||-18,500||15,100||1,000||-10,000||52,400||-65,000||-111,000||151,000|
|Net Cash Provided By Used In Operating Activities||802,700||833,100||852,900||833,000||849,200||854,000||924,000||569,000|
|Net Cash Provided By Used In Investing Activities|
|Payments To Acquire Property Plant And Equipment||189,900||311,300||209,900||164,800||209,300||148,000||152,000||119,000|
|Proceeds From Divestiture Of Businesses||-||0||0||147,400||42,000||50,000||181,000||1,014,000|
|Adjustmentsto Proceeds From Saleof Business||-||-||-||-||0||0||11,000||25,000|
|Net Cash Provided By Used In Investing Activities||-250,100||-1,417,500||-248,900||-19,700||-162,600||-3,284,000||-1,000||870,000|
|Net Cash Provided By Used In Financing Activities|
|Proceeds From Borrowings||0||852,100||9,400||18,200||34,200||3,683,000||61,000||85,000|
|Repayments Of Unsecured Debt||-||-||-||-||-||954,000||730,000||584,000|
|Proceeds From Stock Options Exercised||18,900||24,500||28,200||97,900||141,300||47,000||44,000||54,000|
|Payments For Repurchase Of Common Stock||208,000||256,100||473,500||414,900||309,400||150,000||0||710,000|
|Payments Of Dividends Common Stock||115,000||127,000||139,600||164,700||180,300||198,000||252,000||262,000|
|Proceeds From Payments For Other Financing Activities||-||-||-||-||-9,000||-55,000||-16,000||-21,000|
|Net Cash Provided By Used In Financing Activities||-380,900||492,800||-609,800||-839,700||-448,100||2,373,000||-893,000||-1,438,000|
|Effect Of Exchange Rate On Cash And Cash Equivalents||2,300||3,300||-5,100||-8,600||1,500||-23,000||-24,000||-4,000|
|Cash And Cash Equivalents Period Increase Decrease||174,000||-88,300||-10,900||-35,000||240,000||-80,000||6,000||-3,000|
|Cash And Cash Equivalents At Carrying Value||-||-||356,000||321,000||561,000||481,000||487,000||484,000|
Peers - Search, Detection, Navigation, Guidance, Aeronautical, and Nautical Systems and Instruments (3812)
AERGP / Applied Energetics, Inc.
FLIR / FLIR Systems, Inc.
GLEC / Global Ecology Corp.
GRMN / Garmin Ltd.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET